Federal Circuit court halts delisting of Jazz narcolepsy drug patent from the Orange Book

The US Court of Appeals for the Federal Circuit yesterday ordered a halt to the delisting of a key patent for Jazz Pharmaceuticals’ narcolepsy drug in the FDA’s Orange Book, reversing a Delaware district court judge’s decision last month to remove the patent from the Orange Book.